

REPORT ON NEW COST PROJECT CA 21140 – INTERCEPTION OF ORAL CANCER DEVELOPMENT

Ingrīda Čēma¹, Madara Dzudzilo¹, Marine Benaissa², Antonella Cardone³, Senada Koljenovic⁴,
Pierre Saintigny⁵

¹Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Rīga Stradiņš University

²Department of Translational Medicine, Claude Bernard University Lyon

³Cancer Patients Europe

⁴Department of Pathology, University of Antwerp; Antwerp University Hospital

⁵Cancer Research Center of Lyon, Claude Bernard University Lyon

Objectives. The oral cavity is the most common site of squamous cell carcinoma, the precursor of which is oral potentially malignant disorder (OPMD). Interception of oral cancer development COST Action aims to develop a new multidisciplinary approach and to reorganize disease care management by establishing support for people affected by OPMD, which will result in prevention of malignant transformation.

Materials and Methods. The working groups of Action will be organized in several levels: of the patients' medical histories; of the caregivers; of the clinical and translational researchers; at the level of the population. The network will bring together participants from different 23 COST countries with 108 participants

Results. The current situation in this field shows the need to perform disease trajectory analysis based on healthcare data from population-wide registries on country levels. To improve patient's care based on disease management and develop electronic-Health tools for patients' monitoring. Objective methods to improve early detection of OPMD will be explored. The development of standardized procedures for sample collection, characterization, and molecular risk-assessment to improve patient stratification will be coordinated, as well as development of clinical models to evaluate new pharmacological approaches for early detection of cancer. There is a need to understand the socio-economic and ethical impacts of developing personalized preventive medicine.

Conclusions. In accordance with the Action aims, new multidisciplinary approach will be developed, the research interaction and collaboration between research groups and industrials, will be facilitated. Disease care management by establishing support for people affected by OPMD will be reorganized, thus preventing malignant transformation as early as possible. The cooperation with the policy makers and regulatory bodies to implement the Actions findings into everyday clinical practice and life will be facilitated. An innovative approach to address the prevention challenges beyond weaning programs and anti-smoking/drinking advertising campaigns is foreseen.